Arcturus Therapeutics, Inc.
10628 Science Center Drive
Suite 250
San Diego
CA
92121
United States
90 articles with Arcturus Therapeutics, Inc.
-
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
5/9/2022
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the first quarter ended March 31, 2022, and provided corporate updates.
-
CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
5/5/2022
Arcturus Therapeutics Holdings Inc. provided updated data from its Phase 1/2 booster clinical trial showing durability of antibody response with ARCT-154 for at least three months after low-dose booster.
-
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
4/27/2022
Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter ended March 31, 2022 after the market close on Monday, May 9 and will also host a conference call and webcast at 4:30 pm Eastern Daylight Time on May 9, 2022.
-
It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Apr 23, 2022
4/23/2022
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 60,400 shares of Arcturus common stock to four newly-hired employee.
-
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
4/20/2022
Arcturus Therapeutics Holdings Inc. today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Mar 19, 2022
3/19/2022
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 20,000 shares of Arcturus’ common stock to two newly-hired employee.
-
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
3/14/2022
Arcturus Therapeutics Holdings Inc. announced that Company management will participate in a Fireside Chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 1:35 p.m. ET.
-
Five Top CEOs to Watch in 2022
2/23/2022
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders. -
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/19/2022
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 11,200 shares of Arcturus’s common stock to three newly-hired employees.
-
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
2/16/2022
Arcturus Therapeutics Holdings Inc. today announced that it will release its financial results for the quarter and year ended December 31, 2021 after the market close on Monday, February 28.
-
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
2/8/2022
Arcturus Therapeutics Holdings Inc. announced that members of the Company’s management team will be participating in the SVB Leerink 11th Annual Global Healthcare Conference 2022.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
1/25/2022
Arcturus Therapeutics Holdings Inc. today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.
-
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
1/24/2022
Arcturus Therapeutics Holdings Inc. today announced updated data from clinical development programs for ARCT-154 and ARCT-165.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 22, 2022
1/22/2022
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 5,800 shares of Arcturus’s common stock to one newly-hired employee.
-
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 18, 2021
12/18/2021
Arcturus Therapeutics Holdings Inc. announced that the Compensation Committee of the Company’s Board of Directors and the Company’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 13,800 shares of Arcturus’ common stock to three newly-hired employees.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
12/16/2021
Arcturus Therapeutics Holdings Inc. today announced new data and updates from clinical development programs for ARCT-154 and ARCT-165.
-
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
12/13/2021
Arcturus Therapeutics Holdings Inc. today announced the appointment of Jing Marantz, M.D., Ph.D., M.B.A., an experienced biopharma industry executive, to its Board of Directors.